ONL Therapeutics
Biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
Launch date
Employees
Market cap
-
Enterprise valuation
€236—355m (Dealroom.co estimates Sep 2024.)
Ann Arbor Michigan (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$500k | Seed | ||
N/A | $1.4m | Grant | |
N/A | $916k | Debt | |
$1.0m | Grant | ||
$4.3m | Series A | ||
$3.0m | Convertible | ||
$46.9m | Series B | ||
* | $15.0m Valuation: $235m | Series C | |
* | $65.0m | Series D | |
Total Funding | €125m |
Related Content
Recent News about ONL Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.